Taiwan has given emergency use authorization (EUA) to a COVID-19 vaccine developed by Taiwan-based Medigen Vaccine Biologics Corp. after a panel of experts felt its data on the vaccine's production of antibodies in Phase 2 trials met local standards.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
Scholars split on prosecutor's nomination as head of top judicial body
07/03/2025 06:28 PM - Politics
- Business
Cabinet approves new incentives to attract investment in Taiwan
07/03/2025 05:32 PM - Science & Tech
Taiwanese team develops new treatment for triple-negative breast cancer
07/03/2025 05:23 PM - Science & Tech
Taiwan study finds early screening lowers colorectal cancer risk
07/03/2025 05:05 PM